Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.

ABSTRACT:

Background

Age-related macular degeneration (AMD) is a common cause of severe vision loss in people 55 years and older.

Objectives

The objective of this review was to investigate the effects of anti-VEGF (vascular endothelial growth factor) modalities for treating neovascular AMD.

Search strategy

We searched CENTRAL, MEDLINE, EMBASE and LILACS. We handsearched ARVO abstracts for 2006, 2007 for ongoing trials.

Selection criteria

We included randomized controlled trials (RCTs).

Data collection and analysis

Two review authors independently extracted data. We contacted trial authors for additional data. We summarized outcomes as relative risks (RR), number needed to treat (NNT) and weighted mean differences.

Main results

We included five RCTs of good

SUBMITTER: Vedula SS 

PROVIDER: S-EPMC4267250 | biostudies-literature | 2008 Apr

REPOSITORIES: biostudies-literature